DMS Group Secures up to €20M from EIB for Medical Imaging
Diagnostic Medical Systems (DMS Group) has secured a financing line of up to €20M from the European Investment Bank (EIB), structured in three tranches and supported by the European Union's InvestEU program. This funding is aimed at accelerating the development of innovative medical imaging solutions.
Financing Agreement Details
DMS Group, a specialist in high-performance medical imaging systems for digital radiology and bone densitometry, has entered into a financing agreement with the European Investment Bank. The credit line is structured in three tranches: €4.0M (Tranche A), €6.0M (Tranche B), and €10.0M (Tranche C). This financing is part of the InvestEU program with the support of the European Union. Tranche A will be drawn as soon as the contractual and legal conditions are met. Tranches B and C, available 18 months and 36 months after the contract signing respectively, are contingent on operational, economic, R&D, and regulatory milestones and remain at the discretion of DMS Group.
Repayment and Interest Terms
All tranches are amortizable over a period of 4 years following a 2-year grace period from the drawdown date, resulting in a total maturity of 6 years. Tranche A carries a fixed annual interest rate of 5%, with a portion of the interest (3%) deferred and paid at maturity. The financing includes the issuance of warrants (BSA) for the benefit of the EIB. For Tranche A, the exercise price of the BSA will be equal to 99% of the volume-weighted average price of DMS Group's stock over 20 trading days preceding the issue date. The BSA can be exercised after the maturity of Tranche A and will have a lifespan of 14 years. Based on the closing price as of March 26, 2026, the total number of shares resulting from the potential exercise of the BSA issued at the time of the Tranche A drawdown would represent 4.21% of the share capital.
Support for Long-Term Innovation Program
The financing supports the group's long-term innovation program focusing on the next generation of medical imaging solutions. The resources will contribute to accelerating the development of innovative solutions for European and international markets, including a new generation of digital RF rooms, a bone densitometer, motorized and non-motorized mobile radiology equipment, mobile solutions for operating rooms (surgical C-arms), and the integration of solutions for medical image interpretation using artificial intelligence. The financing will also strengthen the industrial capabilities of the Gallargues-le-Montueux production and assembly site and support regulatory steps, market access, and intellectual property protection efforts. It will accompany the commercial launch of new solutions between 2026 and 2030. The expenditures associated with this investment program will be primarily incurred in France.
